With the flexible nature of a robust technology platform and the ability to create a variety of disruptive ingredients serving the health sector the opportunities to expand within it are significant.

In April 2016, Amyris announced that it had executed a Biofene® supply agreement with a global nutraceuticals company. Under the five-year $100 million supply agreement, the customer intends to convert our Biofene into a nutraceutical product.

This new, highly disruptive partner application for our flexible Biofene ingredient ─ which supports multiple broad-based market applications ─ is an example of growing demand for Biofene and Biofene-derivative applications for large markets, including nutraceuticals.